Form 4: Revolution Medicines' CEO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On October 1, 2024, Mark A. Goldsmith, the CEO of Revolution Medicines, exercised stock options to acquire 10,000 shares of common stock at a price of $4.09 per share.
- Simultaneously, Goldsmith sold 7,978 shares at a weighted average price of $44.7993 and 2,022 shares at a weighted average price of $45.4566.
- These transactions were executed under a 10b5-1 trading plan adopted on December 1, 2023.
- Following these transactions, Goldsmith directly owns 300,170 shares of common stock and indirectly owns 465,604 shares through a trust.
- He also directly holds options to purchase 271,229 shares of common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The market reaction will depend on the overall context and investor confidence in the company.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant way for insiders to manage their stock holdings.
Risks
- While the transactions are part of a pre-arranged plan, significant insider selling could be perceived negatively by the market.
Industry Context
Insider transactions are common, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. The market will likely assess the transactions in light of Revolution Medicines' overall performance and future prospects.
Stakeholder Impact
- Shareholders may scrutinize the transactions for insights into management's view of the company's valuation.
- Employees may be interested in the executive's stock activity as a signal of company health.
Key Dates
| Date | Description |
|---|---|
| 2011-12-15 | Date of the Goldsmith Children's 2011 Irrevocable Education Trust |
| 2023-03-13 | Date the Stock Option (Right to Buy) was exercisable |
| 2023-12-01 | Date Mark A. Goldsmith adopted the 10b5-1 trading plan |
| 2024-03-12 | Expiration date of the Stock Option (Right to Buy) |
| 2024-10-01 | Date of the reported transactions (option exercise and stock sales) |
| 2024-10-03 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.